Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 20/3012% below fair value
$167.40−2.00 (-1.18%)
Close on Nov 13, 2026Market cap $17.02BP/E 24.8Yield –
Neurocrine Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Neurocrine Biosciences's ebitda for the twelve months ending Sep 30, 2019 was $51.91M, up 71.3% year over year. For fiscal 2018 it was $40.82M. The highest annual figure on record is $40.82M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $40.82M | – |
| FY2017 | Dec 31, 2017 | -$128.96M | – |
| FY2016 | Dec 31, 2016 | -$145.92M | – |
| FY2015 | Dec 31, 2015 | -$93.19M | – |
| FY2014 | Dec 31, 2014 | -$63.58M | – |
| FY2013 | Dec 31, 2013 | -$49.01M | -2428.1% |
| FY2012 | Dec 31, 2012 | $2.11M | -93.9% |
| FY2011 | Dec 31, 2011 | $34.62M | – |
| FY2010 | Dec 31, 2010 | -$12.29M | – |
| FY2009 | Dec 31, 2009 | -$50.49M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2019 | Sep 30, 2019 | $92.11M | +66.3% |
| Q2 FY2019 | Jun 30, 2019 | $36.19M | – |
| Q1 FY2019 | Mar 31, 2019 | -$99.43M | – |
| Q4 FY2018 | Dec 31, 2018 | $23.05M | +83.8% |
| Q3 FY2018 | Sep 30, 2018 | $55.40M | – |
| Q2 FY2018 | Jun 30, 2018 | -$969.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$36.66M | – |
| Q4 FY2017 | Dec 31, 2017 | $12.54M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.38M | – |
| Q2 FY2017 | Jun 30, 2017 | -$56.68M | – |
| Q1 FY2017 | Mar 31, 2017 | -$79.44M | – |
| Q4 FY2016 | Dec 31, 2016 | -$45.81M | – |
See a number that looks wrong?